Michael Barbella, Managing Editor10.05.23
MediPines has expanded its MediPines AGM100 non-invasive pulmonary gas exchange analyzer technology to Southeast Asia through a sales and marketing agreement with Ambica International, a regional pharmaceutical and medical device provider.
The MediPines AGM100 is a U.S. Food and Drug Administration (FDA)-cleared, advanced pulmonary gas exchange technology that provides Oxygen Deficit, a non-invasive respiratory impairment severity measurement and surrogate for the alveolar to arterial oxygen difference (AaDO2). It also measures gPaO2, PETCO2, and other sensitive levels of pulmonary gas exchange. The technology provides reliable, discriminative readings that enable real-time decision support for healthcare providers during times of surging respiratory patients and medical staff shortages.
The World Health Organization (WHO) designated the MediPines AGM100 as a notable innovative health technology for treating global priority diseases. The easy-to-use, portable system is being utilized in emergency departments and throughout hospitals' continuum of care.
“Healthcare systems are asking for efficient ways to assess and treat respiratory patients,” MediPines CEO Steve Lee said. “Consistent with the WHO assessment, we believe our technology will help patients in the global south as part of the broader effort to advance respiratory medicine, combat the rising chronic respiratory disease burden, and prepare for future respiratory pandemic events cost effectively.”
Orange County, Calif.-based MediPines is a pioneer in non-invasive pulmonary gas exchange technology. MediPines AGM100 is used by medical providers and clinicians to raise diagnostic accuracy, improve treatment decisions, and accelerate healthcare decision-making. The company is FDA-registered and California medical device manufacturing licensed (CDPH). All products are manufactured in a MDSAP/ISO13485 certified facility.
The MediPines AGM100 is a U.S. Food and Drug Administration (FDA)-cleared, advanced pulmonary gas exchange technology that provides Oxygen Deficit, a non-invasive respiratory impairment severity measurement and surrogate for the alveolar to arterial oxygen difference (AaDO2). It also measures gPaO2, PETCO2, and other sensitive levels of pulmonary gas exchange. The technology provides reliable, discriminative readings that enable real-time decision support for healthcare providers during times of surging respiratory patients and medical staff shortages.
The World Health Organization (WHO) designated the MediPines AGM100 as a notable innovative health technology for treating global priority diseases. The easy-to-use, portable system is being utilized in emergency departments and throughout hospitals' continuum of care.
“Healthcare systems are asking for efficient ways to assess and treat respiratory patients,” MediPines CEO Steve Lee said. “Consistent with the WHO assessment, we believe our technology will help patients in the global south as part of the broader effort to advance respiratory medicine, combat the rising chronic respiratory disease burden, and prepare for future respiratory pandemic events cost effectively.”
Orange County, Calif.-based MediPines is a pioneer in non-invasive pulmonary gas exchange technology. MediPines AGM100 is used by medical providers and clinicians to raise diagnostic accuracy, improve treatment decisions, and accelerate healthcare decision-making. The company is FDA-registered and California medical device manufacturing licensed (CDPH). All products are manufactured in a MDSAP/ISO13485 certified facility.